Clinical Trails

The Phase 1/2a BLUESTAR trial showed promising results for puxitatug samrotecan (Puxi-Sam), a B7-H4-targeting antibody-drug conjugate developed for advanced gynecologic cancers. The drug delivers a topoisomerase 1 inhibitor directly to tumor cells expressing B7-H4, a protein commonly found in endometrial and ovarian cancers. At the recommended 2.4 mg/kg dose, Puxi-Sam achieved an objective response rate […]

The phase 1 NEXUS-01 trial demonstrated encouraging activity for LY4052031, a next-generation Nectin-4-targeting antibody-drug conjugate (ADC) for metastatic urothelial carcinoma. Designed to overcome resistance to enfortumab vedotin (EV), LY4052031 uses a novel topoisomerase 1 inhibitor payload. Among heavily pretreated patients previously exposed to EV, the drug achieved an objective response rate (ORR) of 33% and

The phase 3 SUCCESSOR-2 trial showed that adding mezigdomide, an oral CELMoD, to carfilzomib and dexamethasone significantly improved outcomes for patients with relapsed or refractory multiple myeloma. The triplet regimen doubled median progression-free survival to 18.0 months compared with 8.3 months for carfilzomib and dexamethasone alone, reducing the risk of disease progression or death by

A Phase 1 trial of RD118, a novel fully human anti-GPRC5D CAR T-cell therapy, showed strong and durable responses in heavily pretreated patients with relapsed or refractory multiple myeloma. The study enrolled 18 patients, many with high-risk disease, including prior BCMA CAR T failure. With a median follow-up of 17 months, the overall response rate

Early results from the phase 2 CONVERGE trial show that JNJ-1900 can be safely combined with standard concurrent chemoradiotherapy for patients with stage 3 unresectable non–small cell lung cancer. JNJ-1900 is a nanoparticle-based radioenhancer injected directly into tumors or lymph nodes before radiation treatment. Investigators reported that the injection procedure was feasible and did not

A phase 1b/2 trial showed promising results for a new combination therapy in patients with HER2-positive metastatic breast cancer who had already failed treatment with Enhertu. The study evaluated zanidatamab-hrii, a HER2-targeted bispecific antibody, together with evorpacept, a CD47 blocker, in 24 heavily pretreated patients. Overall, the response rate was 33.3%, but patients with centrally

An ongoing phase 1b/2a clinical trial is showing encouraging early results for Nadunolimab combined with azacitidine in patients with high-risk myelodysplastic syndrome (MDS), and with azacitidine plus Venetoclax in relapsed or refractory acute myeloid leukemia (AML). The investigator-initiated study, conducted at MD Anderson Cancer Center, has completed its phase 1b dose-escalation stage without any dose-limiting

An analysis of reconstructed individual patient data from the phase 3 EORTC 1333/PEACE-3 trial found that combining Enzalutamide with Radium-223 produced a delayed but meaningful long-term survival benefit in patients with metastatic castration-resistant prostate cancer (mCRPC). Researchers reported that the combination showed little survival advantage during the first 18 months of active treatment, but benefits

Blinded results from Part A of the phase 2b/3 MIRACLE trial showed encouraging activity for Annamycin combined with Cytarabine in patients with relapsed or refractory Acute Myeloid Leukemia receiving second-line treatment. The study compared the combination with cytarabine plus placebo in patients aged 18 to 80. Among 45 evaluable patients, the pooled composite complete remission

A phase 2 trial found that combining Camrelizumab and Apatinib showed promising results in patients with refractory chordoma, a rare and aggressive spine cancer. The study included 33 patients. The combination achieved an objective response rate of 24.2% by RECIST 1.1 and 48.5% by Choi criteria, with a disease control rate of 90.9%. Median progression-free